Palomino Laboratories (PALX) director buys 12,500 shares in open market

Rhea-AI Filing Summary

Palomino Laboratories Inc. director Steven Denbaars made an open-market purchase of 12,500 shares of Common Stock at $4.00 per share on April 20, 2026. After this transaction, he directly owns 1,762,500 shares of the company’s Common Stock.

Insider Trade Summary

Net Buyer: 12,500 shares ($50,000)

Net Buy 1 txn

Insider Denbaars Steven

Role null

Bought 12,500 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$4.00	$50K

Holdings After Transaction: Common Stock — 1,762,500 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 12,500 shares Purchase price: $4.00 per share Total shares after transaction: 1,762,500 shares

3 metrics

Shares purchased 12,500 shares Open-market purchase on April 20, 2026

Purchase price $4.00 per share Price paid in April 20, 2026 transaction

Total shares after transaction 1,762,500 shares Direct holdings following reported purchase

Key Terms

open-market purchase, Common Stock, non-derivative

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title is listed as "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type is described as "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denbaars Steven

(Last) (First) (Middle)

313 BRYANT COURT

(Street)

PALO ALTO, CALIFORNIA 94301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Palomino Laboratories Inc. [ NONE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		P		12,500	A	$4	1,762,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Steven Denbaars	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Steven Denbaars report at Palomino Laboratories (PALX)?

Director Steven Denbaars reported an open-market purchase of 12,500 shares of Palomino Laboratories Common Stock at $4.00 per share on April 20, 2026. This filing reflects a direct increase in his personal shareholdings in the company.

How many Palomino Laboratories (PALX) shares does Steven Denbaars own after this Form 4?

Following the reported transaction, Steven Denbaars directly owns 1,762,500 shares of Palomino Laboratories Common Stock. This total includes the 12,500 shares he bought on April 20, 2026 at $4.00 per share in an open-market purchase.

What was the price paid in the Palomino Laboratories (PALX) insider purchase?

In the reported transaction, Steven Denbaars paid $4.00 per share for 12,500 shares of Palomino Laboratories Common Stock. The purchase was classified as an open-market transaction, meaning the shares were bought on the public market rather than via a grant.

Was the Palomino Laboratories (PALX) insider trade a buy or a sell?

The reported Palomino Laboratories insider trade was a buy. Director Steven Denbaars executed an open-market purchase of 12,500 Common Stock shares at $4.00 per share, increasing his direct holdings to 1,762,500 shares after the transaction.

Is Steven Denbaars’ ownership in Palomino Laboratories (PALX) direct or indirect?

The Form 4 indicates that Steven Denbaars’ 1,762,500 Palomino Laboratories shares are held as direct ownership. The transaction is coded with a direct ownership type, meaning the shares are attributed to him personally rather than through an intermediate entity.